Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use

Inclusion criteria

• Diagnosed with type 1 diabetes (World Health Organization criteria) for at least 24 months
• Treated with continuous subcutaneous insulin infusion (CSII) therapy for the previous 6 months
• Mean total daily insulin dose for 3 days prior to screening less than or equal to 46 units/day if using a 300-Unit reservoir, less than or equal to 30 units/day if using a 200 unit reservoir, or less than or equal to 26 units/day if using a 180 unit reservoir
• Baseline body mass index (BMI) less than or equal to 35.0 kilograms per meter squared (kg/m2)
• Baseline glycated hemoglobin A1c (HbA1c) 5% to 9%

Exclusion criteria

• Impaired renal function (serum creatinine greater than or equal to 2.0 milligrams per deciliter (mg/dL))
• Legal blindness
• Have had any episode in the 12 months prior to screening of hypoglycemic coma, seizures, or disorientation
• Have had hypoglycemia unawareness (routinely asymptomatic at blood glucose less than 45 mg/dL [2.5 millimoles per liter (mmol/L)]) in the 12 months prior to screening.
• Have had any emergency room visits or hospitalizations due to poor glucose control in the 12 months prior to screening.
• Have had a pump-related infusion site abscess in the 12 months prior to screening.
• Have had multiple, clinically significant occlusions as judged by the investigator.
• Have had any infection with Staphylococcus aureus in the past 5 years
• Have one of the following concomitant diseases: presence of clinically significant hematologic, oncologic, renal, cardiac, hepatic, or gastrointestinal disease, or any other serious disease considered by the investigator to be exclusionary.
• Participants with malignancy other than basal cell or squamous cell skin cancer who have not yet been treated, are currently being treated, or who were diagnosed less than 5 years ago.
• Have had a blood transfusion or severe blood loss within the 3 months prior to screening or have known hemoglobinopathy, hemolytic or sickle cell anemia, or any other traits of hemoglobin abnormalities known to interfere with HbA1c methodology.
• Are receiving chronic systemic glucocorticoid therapy, or have received such therapy within the 4 weeks preceding screening.
• Have an irregular sleep/wake cycle in the investigator's opinion.
• Have a known hypersensitivity or allergy to any of the study insulins or their excipients
• Are breastfeeding or pregnant, or intend to become pregnant during the course of the study, or are sexually active women of childbearing potential not actively practicing birth control by a method determined by the investigator to be medically acceptable.
• Are currently enrolled in, or discontinued within the last 30 days from a clinical trial involving off-label use of an investigational drug or device, or currently enrolled in any other type of medical research not to be scientifically or medically compatible with this study.
• Are unwilling or unable to comply with the use of a data collection device to directly record data from the participant.